source
- Genentech pays $45M upfront to DualityBio for ADC platform targeting resistant cancersGenentech has agreed to pay DualityBio $45 million upfront for rights to its antibody‑drug conjugate (ADC) technology, with the agreement offering more than $1 billion in potential milestone paymen…
- CEPI pledges up to $16.5M to advance Egyptian biotech's Ebola vaccine candidateCEPI has committed up to $16.5 million to help bring Minapharm’s Bundibugyo Ebola vaccine candidate into clinical testing. The funding will support preclinical work and an early-stage human trial…